EUVIMEDEUVIMED entdecken
Crossref

Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration

Yousif Subhi iD, Miklos Schneider iD, Javad Nouri Hajari, Morten la Cour

Acta Ophthalmologica · 2024

DOI: 10.1111/aos.16709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Yousif Subhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Intravitreal Injections, Wet Macular Degeneration. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The Observe‐and‐Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age‐related macular degeneration (AMD).

Methods

This was a retrospective registry‐based study of treatment‐naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow‐up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections.

Results

Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow‐up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4–6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%.

Conclusion

After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label‐recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorIntravitreal InjectionsWet Macular DegenerationTomography, Optical CoherenceVisual AcuityAngiogenesis InhibitorsHumansRetrospective StudiesFemaleMaleAgedFollow-Up StudiesAged, 80 and overFluorescein AngiographyMacula LuteaTreatment OutcomeTime FactorsDose-Response Relationship, DrugRegistriesFundus OculiDrug Administration ScheduleVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

afliberceptneovascular age‐related macular degenerationobserve‐and‐planreal‐world datatreatment regimen

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
  • Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
  • Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Yousif Subhi, Miklos Schneider

Zitieren

APA

Subhi, Y., Schneider, M., Hajari, J. N., & la Cour, M. (2024). Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration. Acta Ophthalmologica. https://doi.org/10.1111/aos.16709

Vancouver

Subhi Y, Schneider M, Hajari JN, la Cour M. Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration. Acta Ophthalmologica. 2024. doi:10.1111/aos.16709

BibTeX
@article{Subhi2024,
  author = {Subhi, Yousif and Schneider, Miklos and Hajari, Javad Nouri and la Cour, Morten},
  title = {Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration},
  journal = {Acta Ophthalmologica},
  year = {2024},
  doi = {10.1111/aos.16709}
}
Kostenlos starten →